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Chronic graft-versus-host disease (cGVHD) has the potential to cause signiﬁcant morbidity and mortality in
people who undergo allogeneic hematopoietic stem cell transplantation. Management of complications due
to cGVHD can be challenging because of multiorgan involvement and variable presentation of the disease.
This paper outlines the diagnosis and management of musculoskeletal, neurologic, and cardiopulmonary
manifestations of cGVHD that have the potential to cause profound functional impairment and that may
signiﬁcantly impact quality of life and lifespan. Expert evaluation by a physical medicine and rehabilitation
physician and multidisciplinary team may be beneﬁcial in the treatment of the disease sequelae, and ex-
amples of speciﬁc rehabilitation interventions are described.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is the most
common long-term complication after allogeneic hemato-
poietic stem cell transplantation (HSCT) and it affects about
50% of patients [1]. Its pathophysiology is largely unknown
and unlike acute GVHD, it can affect almost any organ
system. The treatment for cGVHD, which almost invariably
involves long-term administration of corticosteroids, causes
additional toxicity and contributes to the complexity of this
syndrome. Thus, cGVHD can signiﬁcantly increase non-
relapse mortality and morbidity, with a profound impact on
quality of life in patients who are otherwise in remission of
their malignancy.
Little research has been performed on the treatment of
the physical impact of cGVHD and the resulting functional
impairment in these otherwise cancer-free transplantation
survivors. A Medline search of the terms disability or reha-
bilitation combined with the term graft-versus-host diseasedgments on page 806.
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ty for Blood and Marrow Transplantation.returned 45 items as of the writing of this article, of which
less than one-half related primarily to the topic. The 2005
National Institutes of Health Consensus statement for clinical
trials in cGVHD was the ﬁrst effort to bring attention to this
problem, outlining the degree of impairment and evidence-
based ancillary and supportive care [2]. Given the dearth of
research in this area and lack of literature describing
collaboration between bone marrow transplantation (BMT)
oncologists and physiatrists, it is likely that physical medi-
cine and rehabilitation (PM&R) physicians are underutilized
in the comanagement of patients with cGVHD. Possible
reasons for the lack of research focus in this area are outlined
in Table 1.
The impact of cGVHD on physical function can be pro-
found and it may be difﬁcult to distinguish from other
transplantation-related long-term complications. When
these effects are measured as performance status, they inti-
mately correlate with survival. Unfortunately, the exact
impact of physical rehabilitation on nonrelapse mortality,
quality of life, and systemic therapy in cGVHD is largely un-
explored. The positive effects of physical activity in both
health and disease, as demonstrated in numerous other
disorders, warrants a close interaction with the rehabilita-
tion team. Although there are no speciﬁc trials in cGVHD,
there is overwhelming evidence for the beneﬁt of team
Table 1
Challenges and Shortcomings of Research on Rehabilitation for cGVHD
Challenges in Studying Rehabilitation Issues in cGVHD
Chronic GVHD has not traditionally been a focus of PM&R (compared
with stroke, spinal cord injury, amputation, etc)
Polymorphic clinical presentation, so outcome measurements and
standardization of trials is difﬁcult
Patient populations are essentially limited to tertiary care centers
with a BMT program
PM&R research has traditionally focused primarily on orthopedic,
post-traumatic, and neurologic diagnoses
BMT physicians may not be familiar with PM&R physician skill sets,
may not collaborate frequently
Examples of Topics in cGVHD Rehabilitation Needing More Research
Effects of aerobic exercise on reversing cGVHD
Bracing and/or splinting trials for sclerotic cGVHD
Inpatient rehabilitation and the beneﬁts of multidisciplinary
assessment
Prevalence of steroid myopathy and its impact on patient function
and health
Correlation between loss of physical function and hospital
readmission
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team rehabilitation is led by a physiatrist and involves
specialized nursing, physical and occupational therapy, psy-
chosocial support, and other allied health professionals as
needed. This can be performed ad hoc on an outpatient basis
or in an acute inpatient rehabilitation unit for patients un-
able to be discharged home because of physical limitations.
Postacute facilities (eg, subacute rehabilitation and/or skilled
nursing facilities) provide less intense therapy for these
debilitated and sick patients, and evidence is growing that
morbidity and mortality are increased in patients with
similar diagnoses managed in a postacute facility instead of
an acute inpatient rehabilitation facility [6,7].
This manuscript focuses on the complications from
cGVHD or its therapy, which can result in loss of physical
functionality, and medical rehabilitation as a treatment.
Other forms of supportive care and systemic therapy are
beyond the scope of this review. Manifestations of cGVHD
and their rehabilitation-based treatment are divided by or-
gan system (see Table 2).SKIN AND JOINTS
Clinical Manifestations
Cutaneous involvement is the most common manifesta-
tion of cGVHD, affecting about 90% to 100% of patients, and
can lead to a great deal of functional impairment [8]. Cuta-
neous cGVHD can be classiﬁed into 2 distinct anatomic
subcategories, dermal and fascial, though there is often
coinvolvement of both [9].Table 2
Common Rehabilitation Issues in cGVHD
Organ Problem Intervention
Skin/fascia Sclerodermatous contractures OT for ROM an
may have nega
Muscle Myopathy PT for fall prev
(canes, walkers
Bone Osteoporosis Core stabilizati
Peripheral nervous system Peripheral neuropathy Bracing for mo
(proper footwe
Cardiopulmonary Physical deconditioning Exercise progra
speciﬁc issues i
OT indicates occupational therapy; ROM, range of motion; PT, physical therapy.There are 2 typical manifestations of dermal cGVHD:
lichenoid and sclerodermatous. Lichenoid manifestations
include a maculopapular rash resembling lichen planus and
have the potential to affect the oral cavity and vaginal mu-
cosa. Sclerodermoid cGVHD, on the other hand, mimics
systemic sclerosis and can manifest as skin tightening, at-
rophy, blistering, ulceration, loss of sweat glands, and joint
contracture. The presentation can range from mild to sig-
niﬁcant involvement and the severity of cGVHD is based on
the extent to which the skin and fascia are involved [10].
When the involvement of the skin and/or fascia sur-
rounds joints, it can cause decreased range of motion,
signiﬁcantly restricting a patient’s ability to perform activ-
ities of daily living [9] and contributing to prolonged periods
of immobility. Painful joint contractures may also result,
further impairing function. Edema is often the ﬁrst ﬁnding on
physical exam of fascial involvement in GVHD [2]. Common
joints affected are the wrists, shoulders, ankles, and hips,
with the distal joints often affected ﬁrst. Involvement is
typically symmetric and can be progressive, involving more
areas of the skin and joints over time. cGVHD is an inde-
pendent risk factor for joint destruction and associated pain
and dysfunction [11].
A patient affected by cutaneous cGVHD is already at risk
for decubitus ulcers due to immobility from the disease and/
or its treatment, and thinning of the skin facilitates this
problem. Ulcerations of the skin, either as a direct result of
inﬂammatory destruction of the skin due to cGVHD or as a
result of shear forces or pressure, cause pain and put the
patient at a signiﬁcant risk for cellulitis and osteomyelitis in
this immunosuppressed patient population. Edema can
result from inﬂammatory sweat gland destruction, also
contributing to skin thinning and ulceration in addition to
worsening functional impairment by adding weight in the
extremities. Gastrointestinal GVHD, with loose, frequent
stools, coupled with the inability of a patient to physically get
to a toilet or commode, further complicates this picture and
creates an environment where infection can rapidly spread.
Treating both the GVHD and the weakness from muscle
deterioration is essential. The “Muscle” section below further
discusses this issue.
Treatment
Management options in cutaneous cGVHD are limited and
of variable efﬁcacy, particularly in advanced cases with
marked sclerosis and limitation in the range of motion. The
exact role of rehabilitation at different stages of the disease
remains unknown. Although no randomized control trial for
stretching and splinting has been conducted or shown to be
efﬁcacious in preventing skin and joint contractures, there
are case reports and limited studies that showmild beneﬁt ofd strengthening, splinting, iontophoresis. Surgery likely ineffective and
tive outcomes.
ention and strengthening. Bracing for weak muscles. Adaptive equipment
) as indicated.
on, bracing for pain or stability
tor weakness, nerve stabilizing agents for pain, wound prevention
ar, frequent skin checks)
m (possibly through PT), consider pulmonary or cardiac rehab for
n these organ systems
Table 3
Examples of Orthoses Used in the Treatment of cGVHD
Name Picture Pros Cons
Resting hand splint Figure 1 Holds ﬁngers and hand in extension, easy to put
on and take off
Does not provide an active stretch, unclear if prevents
contractures
Dynamic hand splint Figure 2 Provides a stretch in addition to limiting ﬂexion More difﬁcult to put on and fabricate, unclear efﬁcacy
Ankle foot orthosis Figure 3 Holds ankle in dorsiﬂexion, prevents foot drop/drag Not effective at night, patient may need gait training in
physical therapy
Multipodus (L’nard) boot Figure 4 Provides dorsiﬂexion stretch at night, may prevent
plantarﬂexion contracture
Unclear efﬁcacy, typically not used during ambulation
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pational therapy [12]. One descriptive study of 14 pediatric
patients with cGVHD-related joint contractures showed that
physical therapy and proper use of orthotics improved range
of motion and function to near baseline [13]. This same study
also showed that surgical release of contracted joints was
unsuccessful in improving functional status, and, further-
more, that surgery made the involved joints refractory to
conservative treatment, such as splinting. Splinting can take
many forms, including supportive splints that prevent bad
positioning, splints that create pressure to stretch, and serial
casting or dial-lock splints changed weekly to aggressively
treat severe contractures.
One case report describes successful surgical release of
multiple contracted joints in using Y-V plasties, a technique in
which incisions are cut and reattached in a manner to reduce
tension on the resultant scar. Beneﬁts were apparently seen in
improved range of motion in the patient 9 months after the
operation [14]. Of importance, this case report describes the
muscles and actual joints of the patient as not being obviously
involved in any inﬂammatory process, though the skin
showed chronic inﬂammatory changes. This suggests that
other surgical interventions may have failed secondary to
myofascial and joint inﬂammation and scarring from the
autoimmune process. Because there is no convincing evidence
that surgical correction of contracted joints in cGVHD is a
viable option, conservative management with range-of-
motion exercises, splinting, and strengthening to improve
gross- and ﬁne-motor functioning should be a mainstay of
treatment. More research is needed in this area to assess for
improvement in function with these interventions.
In general, thermal physical modalities are often used to
treat contractures due to other conditions, including sclero-
derma. Theoretically, ice applied for 20 to 30minutes over an
area will decrease pain and might decrease inﬂammation.
Other modalities may have beneﬁcial effects: superﬁcial heat
can loosen bonds within collagen, parafﬁn baths can heat
tissues as deep as 1 cm in the hands and feet, and ultrasound
causes friction, allowing heating and collagen softening even
deeper. Each of these heating modalities must be done with
simultaneous stretching and, theoretically, the heat would
increase rather than decrease inﬂammation. It is important
to note that caution must be taken in patients with friable
skin so as to avoid burns. Clinical trials of thermal modalities
to treat cGVHD seem warranted. Parafﬁn bathing has been
shown to be beneﬁcial for patients with rheumatoid arthritis
in reducing pain and improving range of motion [15]. In
scleroderma, multiple studies show a beneﬁt to using
parafﬁn baths and physical therapy over physical therapy
alone to improve range of motion and reduce pain, evenwith
sustained results [16-18]. No similar studies exist in the
cGVHD population.Iontophoresis, a process by which topical medication is
inﬁltrated into subcutaneous tissue via an electric gradient,
or phonophoresis using ultrasound heating to administer
subcutaneous medication, should also be considered, though
again, no study has been conducted in this patient popula-
tion. Cortisone may be transmitted deep to the epidermis,
potentially penetrating fascial areas of inﬂammation and
facilitating improved outcomes in patients with sclerotic
cGVHD contractures. Alternatively, saline may be used in
iontopohoresis to break up existing scar tissue. Most studies
in the scleroderma population focus on vascular dilation for
digital ischemia [19], though the concept of a local therapy
remains intriguing in the cGVHD population to potentially
limit systemic toxicity.
Response to therapy can be subjective, and using in-clinic
goniometry is the mainstay of joint range assessment.
Obtaining an objective range of motion evaluation can be
difﬁcult and require specialized equipment, making this not
tenable in everyday clinic visits and further complicating
potential studies. The National Institutes of Health visual
scale for assessing range of motion as recommended by the
2005 Consensus Statement [2] has been validated when
assessing changes to the joint motion over time, though it is
better at showing improvement than worsening of disease
[20]. The Barthel Index of Activities of Daily Living is a vali-
dated and reproducible scale that helps to monitor of a pa-
tient’s ability to perform self care, which is especially
important in patients where ﬁne motor or repetitive activ-
ities may be impaired by dysfunction of the hands due to
contracture [21].
Topical treatment for cGVHD involving the skin should
be directed to discrete lesions or wounds, with the goal of
preventing skin breakdown or treating existing lesions [10].
Preventive treatment should focus on treating the common
manifestations of cutaneous cGVHD, including pruritus,
sensitivity to ultraviolet rays, and rash. Topical corticoste-
roids and calcineurin inhibitors, and liberal application of a
ultraviolet-blocking agent containing mexoryl, should be a
mainstay of preventative care. In skinwith breakdown, local
wound dressings that maintain a moist environment pro-
motes healing of the skin and phagocytosis of necrotic
areas. A plastic surgery consultation is warranted in deep,
stage III or IV wounds [22] or in wounds suspected to be
infected.
In summary, in patients with diffuse sclerodermatous
cutaneous and articular involvement of cGVHD, targeted
splinting and range of motion and strengthening exercises
should be initiated. A PM&R consult may be helpful in
coordinating these services and monitoring the patient’s
response to therapy from a functional standpoint. Examples
of orthotic splints that may be used are outlined in Table 3
and shown in Figures 1 through 4.
Figure 1. Resting hand splint. Figure 2. Dynamic hand splint.
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Clinical Manifestations
Muscle mass loss in cGVHD is multifactorial and is most
frequently a result of disuse, deconditioning, or side effects of
immunosuppressive treatment, particularly corticosteroids.
Less frequently, GVHD itself can be the direct or indirect
cause when fascia, peripheral nerves, or less frequently,
muscles are involved [23]. In the more severe forms of
cGVHD, patients may be conﬁned to bed rest for prolonged
periods of time, resulting in both strength and muscle mass
decreases at a rate of about 1% per day [24]. The weight-
bearing lower extremities and low back extensor muscles
are more affected than upper extremities, making it difﬁcult
to begin ambulating after prolonged periods of rest. Skeletal
muscle repair is also hindered because of increased catabo-
lism brought on by higher basal levels of glucocorticoids in
the bloodstream during periods of immobility [25].
Furthermore, patients receiving long-term oral cortico-
steroids are at risk for developing steroid-inducedmyopathy.
Steroid myopathy can be acute or chronic. Acute steroid
myopathy typically occurs within 1 week of high-dose oral
corticosteroid use and can be associated with rhabdomyol-
ysis and pain. The chronic form occurs weeks to months into
prolonged, high-dose steroid administration and is generally
painless. Both forms cause proximal muscle weakness in the
upper and lower extremities and the neck. Patients may
report difﬁculty rising from a seated position or lifting up
utensils to eat. The diagnosis is typically made clinically,
though a muscle biopsy showing selective type II muscle ﬁ-
ber atrophy can be conﬁrmatory [26], and magnetic reso-
nance imaging may show fatty changes in proximal muscles.
Notably, unlike other myopathies, steroid myopathy is not
well detected on electromyography (EMG). Urine studiesmay be diagnostic and may show elevated creatinine in
chronic steroidmyopathy andmyoglobinuria in acute steroid
myopathy.
In addition to steroid myopathy, muscle mass and
strength may be compromised because of an inﬂammatory
myositis, mimicking polymyositis or dermatomyositis, that is
a direct, immune-mediated result of cGVHD [27]. When this
has been described in the literature, it is associated with
tapering of immunosuppressant medications and is associ-
ated with the same genetic markers seen in patients with
this autoimmune disease who have not undergone HSCT
[23]. Typically, this presents with painful, symmetric prox-
imal weakness with increased aldolase and creatine phos-
pokinase seen on blood work. EMG is profoundly abnormal
in the proximal limbs and paraspinal muscles in these dis-
orders. A muscle biopsy is diagnostic [2,28]. Calcineurin in-
hibitors, such as cyclosporine, have been shown to be
effective in the treatment of myositis [28], though speciﬁc
studies in the GVHD population have not been conducted.
In rare instances, myasthenia gravis may develop when
tapering immunosuppressive medication because of pre-
existing autoantibodies against postsynaptic acetylcholine
receptors [29]. This is most commonly seen in patients who
received the HSCT for aplastic anemia [29]. Symptoms typi-
cally are progressive weakness with exertion, with recovery
of strength after rest. Ptosis is a common ﬁrst symptom and
its presence along with generalized weakness may warrant
further workup, such as an EMG that includes repetitive
stimulation studies and blood tests to detect antibodies to
acetylcholine receptors.
Finally, as poor nutritional status is linked to a decline in
muscle strength and mass, decreased energy level, poorer
cognitive performance, and increased risk of complications
Figure 3. Ankle foot orthosis. Figure 4. Multipodus (L’nard) boot.
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must be paid to the nutritional level of patients with cGVHD.
One study found that 40% of patients with GVHD have
malnourishment [31]. The reasons for malnutrition are
multifactorial and may include decreased appetite, poor
absorption of nutrients because of gastrointestinal involve-
ment of the disease or infection, increased catabolism due to
immobility and immunosuppressive treatment, dysphagia,
odynophagia due to oral lesions, depression, and more.
Adequately treating the cause(s) of malnutrition are essential
components to a strengthening program.Table 4
Examples of Therapy Prescriptions for Manifestations of cGVHD
Steroid myopathy/proximal muscle weakness:
PT 2-3 times a week for 4-6 weeks, then re-evaluate. Therapy should
focus on light resistance training, including isometric
strengthening of quadriceps, hamstrings, hip extensors, and hip
abductors. Gait training (with or without an assistive device)
should be performed. Core should be strengthened for spine
stabilization. Home exercise program should be provided and the
patient adequately educated as to how to perform the routine.
Gait instability/fall risk:
PT 2-3 times a week for 4-6 weeks, then re-evaluate. Include balance
and gait training, focusing on ankle proprioceptive feedback and
ambulating with a walker or cane as indicated. Strengthen hip
abductors and quadriceps. Home exercise program.
Sclerotic hand contractures:
OT 1-3 times a week for 4-6 weeks, then re-evaluate. Work on hand
and ﬁnger strengthening and dexterity utilizing modalities such as
clay putty and resistance training. Stretch and strengthen
surrounding musculature. Parafﬁn baths as indicated to improve
stretch. Saline iontophoresis over wrist extensors. Home exercise
program.
Note that these prescriptions are only examples and need to be individu-
alized for each patient.Treatment
Muscular disuse atrophy and steroid-induced myopathy
are often seen in combination and management is difﬁcult
because patients often remain on corticosteroids for pro-
longed periods of time. Usually there is no clinical rationale
for prolonged bed rest without any exercise. In the sickest
patients, tilt table use, sitting at bedside, and upper limb
exercises in bed can help modulate the deconditioning syn-
drome. A portable tilt table may be used on the BMT unit if
the patient is not in an acute inpatient rehabilitation facility.
Passive stretching also preserves muscle mass in addition to
preventing contractures. There should be a low threshold for
early intervention with a rehabilitation program to prevent
muscular disuse atrophy. Resistance exercises should be
introduced into a patient’s exercise regimen, as strength can
be preserved in the setting of steroid myopathy, though
improvement of strength to baseline is unlikely without
discontinuation of corticosteroid therapy [1]. Examples of
physical and occupational therapy prescriptions for common
diagnoses in cGVHD are noted in Table 4.Special considerations for resistance training must be
made for patients with thrombocytopenia, as having a
platelet count below 20,000 platelets/mL is associated with
possible increased bleeding risk. Increased intracranial
pressure, such as with the use of the Valsalva maneuver
whenweight training, has been shown to be associated with
subarachnoid hemorrhage [32] and retinopathy [33], and has
the potential to contribute to bleeding in various other sites
in the body. Lifting restrictions, such as a 10-lb or 4.5-kg
limit, should be initiated in thrombocytopenic patients to
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ical therapist for signs of bleeding during exercise is impor-
tant, and having a PM&R physician concurrently monitoring
a thrombocytopenic patient’s medical condition and
response to therapy may be beneﬁcial. One paper describes
better platelet counts and fewer adverse events when ther-
apy is conducted in the afternoon, though no comprehensive
study has shown this to be the case [34]. Another showed
that while on an acute inpatient rehabilitation unit, 10 of 18
thrombocytopenic patients (less than 100,000 platelets/mL in
this study) had bleeding events, though no speciﬁc exercise
was implicated in causing bleeding [35].
Barriers to adequate nutrition must also be assessed
when optimizing a patient’s strength and conditioning. In
addition to nutritional supplements, dexamethasone rinses
can combat painful oral lesions that inhibit eating, and a
referral to a speech and language pathologist for a swal-
lowing evaluation is important in diagnosing and treating
dysphagia. Medications such as megestrol, 400 to 800 mg
daily, can improve cancer-associated cachexia and provide
modest weight gain [36]. Dronabinol is also often used to
stimulate appetite in cachexia; however, studies have shown
that despite an initial increase in caloric intake, weight gain
was found to be in the form of water or fat instead of lean
body mass [37]. Given the synergistic effects of both exercise
and optimal nutritional intake, it is important that any
rehabilitation plan include attention to both of these factors.
PERIPHERAL NERVES
Clinical Manifestations
cGVHD is associated with several possible neurologic
sequelae, including mononeuropathies, generalized periph-
eral neuropathy, and inﬂammatory neuropathy. A combina-
tion of multiple neuropathies may also result, complicating
diagnosis and treatment. Peripheral neuropathies in general
can be autoimmunemediated, though there is not conclusive
evidence that cGVHD directly causes neuropathy. Neverthe-
less, neuropathy in cGVHD and the absence of other known
etiologies is typically characterized by a symmetric and
painful presentation. Given chronic glucocorticoid use in this
population, peripheral neuropathy from diabetes may
develop. cGVHD has also been shown to cause a neuropathic
process that resembles acute inﬂammatory demyelinating
polyneuropathy (AIDP), and is thought to be a result of direct
inﬁltration of peripheral nerves by donor Tcells [38]. An EMG
can be diagnostic and can show demyelination, axon loss, or
both [39]. The ﬁrst electromyographic sign of AIDP is an
absent F-response, with subsequent ﬁndings of conduction
block and denervation.
Chemotherapy used before transplantation and immu-
nosuppressive medications used to treat cGVHD are themost
common causes of neuropathy. Tacrolimus has also been
associated with a demyelinating peripheral neuropathy that
can cause signiﬁcant pain [40]. EMG can be diagnostic for
peripheral neuropathy but it will not necessarily discern the
cause. Neuropathies caused by chemotherapy are typically
purely sensory or mixed motor and sensory, and about a one
third of patients receiving these medications will develop
some degree of disability [41].
Patients are also at risk of mononeuropathies caused by
nerve entrapment, either by mechanical compression or
fascial inﬂammation. As the inﬂamed fascia and/or skin
surrounding peripheral nerves become ﬁbrosed, the nerve
may become entrapped and damaged. Nerves at high risk for
entrapment are those with little surrounding tissue, such asthe ulnar nerve at the cubital tunnel and peroneal nerve at
the ﬁbular head. A patient with poor muscle mass or fat
reserve, which may be related to the disease course, is
further at risk of peripheral nerve damage by pressure due to
a lack of protective layers around the nerve. The median
nerve at the carpal tunnel can also be damaged due to wrist
ﬂexion contractures. If a peripheral mononeuropathy is
suspected, an EMG may be diagnostic for damage and ul-
trasound may conﬁrm entrapment. Finally, as patients with
cGVHD are often immunocompromised, varicella-zoster vi-
rus reactivation may also occur, resulting in painful neural-
gias often in the distribution of a single nerve.
Treatment
Treatment for peripheral neuropathy associated with
GVHD is supportive. Pain should be managed with gaba-
modifying medications such as gabapentin or pregabalin,
with adjuvant therapy consisting of tricyclic antidepressants
and duloxetine if needed [42]. Pain secondary to post-
herpetic neuralgia speciﬁcally was shown to be relieved with
gabapentin in a randomized placebo-controlled trial [42].
Because medications rarely relieve pain completely in poly-
neuropathy, it is important to balance patient expectations
against medication side effects as one proceeds with multi-
drug therapy, and to discontinue medications that do not
show clear long-term beneﬁt. If starting gabapentin or pre-
gabalin, it is important towatch for lower extremity edema, a
known and relatively common side effect, as it may
compromise skin integrity.
Treatment must also address restoring function with
physical therapy and bracing, as the patient will be at risks
for falls and injury. Sensory neuropathies can impair pro-
prioception and motor neuropathies cause weakness; both
are risk factors for falls. Speciﬁcally, increasing hip abduction
strength and improving ankle proprioception, as can be
accomplished in physical therapy, have a negative correla-
tion with falls [43,44]. Furthermore, patient education about
avoiding falls, as well as home/environmental modiﬁcations
ranging from night lights to removal of slippery carpeting
can decrease falls and minimize their consequences. This is
typically the expertise of occupational therapy, and a referral
to this service for a home safety evaluation may be indicated.
Patients with decreased or absent sensation in their lower
extremities due to neuropathy are also at risk for developing
wounds. The wounds may have difﬁculty healing and can
become infected, leading to osteomyelitis. Trauma can occur
by bumping feet on walls or objects, or from shearing and
repetitive trauma from footwear. Wide-toe diabetic shoes
should be prescribed and ﬁt by a certiﬁed orthotist, and the
patient and/or caregivers should frequently inspect their feet
for wounds. Discrete, painful areas of the feet should be
ofﬂoaded with custom-fabricated orthotic shoe inserts to
normalize gait.
Peripheral mononeuropathies due to compression can be
treatedwith physical therapy and proper positioning, though
in the setting of inﬂammatory fasciitis, surgical release of
scar tissue or local corticosteroid injection may be necessary.
Nerve gliding, a stretching technique used in physical ther-
apy to mobilize peripheral nerves entrapped by scar tissue,
has shown some beneﬁt [45], though this technique has not
been studied speciﬁcally in patients with cGVHD. Pain can be
controlled with similar medications used in generalized pe-
ripheral neuropathies. When splinting and protection fail,
and if medical factors preclude decompressive surgery,
corticosteroid injections into the area of compression may be
S.R. Smith et al. / Biol Blood Marrow Transplant 21 (2015) 799e808 805appropriate. Such injections have been shown to relieve pain
in non-cGVHD patients with carpal tunnel syndrome and
other focal compression neuropathies [46].
If AIDP is conﬁrmed diagnostically with EMG, intravenous
immunoglobulin treatment should be initiated, as well as
supportive therapy, including ventilator assistance for pa-
tients with respiratory compromise. A PM&R consultation
can be helpful in both diagnosis and management of the
disease. It is important to note that intravenous immuno-
globulin has not been shown to be effective in treating
cGVHD, and it should be administered only to patients who
have a comorbidity, such as AIDP, that warrants the treat-
ment and who are greater than 90 days out of HSCT [47].
BONE
Clinical Manifestations
As many as 50% of patients who undergo HSCT develop
osteopenia or osteoporosis, and cGVHD is associated with an
even higher incidence [48]. This is often the result of chronic
glucocorticoid use, a major risk factor for osteopenia and
osteoporosis because of increased bone turnover [49]. Other
risk factors that these patients face that contribute to bone
density loss are calcineurin inhibitor use, chemo- and radi-
ation therapy, gonadal dysfunction, renal dysfunction,
increased marrow turnover due to hematogenous malig-
nancy, and decreased weight-bearing activity [48]. Although
bone density is reduced, it typically decreases to levels seen
in osteopenia and not osteoporosis. Bone density loss in
cGVHD is typically seen more in the femoral heads than the
vertebrae, a distinction when compared with menopausal
osteoporosis [49,50]. This should be noted when evaluating
dual-energy x-ray absorptiometric scan results. The HSCT
itself causes a fundamental alteration of bone mineral
metabolism, with loss seen in the ﬁrst 6 to 12 months, fol-
lowed by ensuing recovery [51].
Prolonged immobility and nutrient deﬁciency, in concert
with paraspinal muscle atrophy, can contribute to debili-
tating back pain [52]. Decreased bone density puts patients
at risk for compression fractures, which would limit their
ability to bear weight and ambulate, as well as cause signif-
icant pain. In patients with axial back pain or known verte-
bral compression fractures, ﬂexion/extension x-rays should
be taken to assess for spinal stability. Potential components
of spinal instability include fractures affecting central or
bilateral vertebral elements, subluxation, involved vertebrae
located at transitional levels (ie, C7 to T1, T11 to L2, L5 to S1),
loss of > 50% vertebral body height, and pain [53].
Finally, patients with cGVHD are also at risk of developing
avascular necrosis (AVN) of joints, most commonly the
femoral heads. This is seen in 4% to 19% of HCT survivors
[54,55] and is associated with many risk factors, including
exposure to glucocorticoids and calcineurin inhibitors, the
disease process itself, older age, and female gender [54].
Higher doses of glucocorticoids are associated with a greater
risk of AVN [55]. Symptoms are typically pain with weight
bearing or movement of the affected joint, and radiographs
may show evidence of edema and bony destruction around
the joints, sometimes with ﬂattening of articular surfaces.
The femoral head is the most common site for developing
AVN, though the humeral head, knees, and ankles are often
affected [51].
Treatment
In addition to medical therapy consisting of vitamin D,
calcium, and possibly bisphosphonate use [56], weight-bearing activity should be initiated to improve bone den-
sity. Short, 20- to 30-minute bursts of walking followed by
periods of rest are effective in improving bone density [57].
Resistance training, such as bicep curls and leg extension
exercises, should also be undertaken to improve bone den-
sity in the long bones of the limbs. Nordic trekking poles can
be useful in promoting an upright posture while simulta-
neously reducing stress on the spine and knees [58].
A patient with difﬁculty walking and/or lower extremity
weakness should be referred to physical therapy to focus on
improving balance and preventing falls (please see the
“Treatment” subsection under “Peripheral Nerves” for more
detail on the prevention of falls, and Table 4 for an example of
a physical therapy prescription for a patient at risk for falls).
Of note, many patients with osteoporosis develop hip ﬂexor
contractures due to sustained forward-ﬂexed posture, so this
should be examined and treated in physical therapy, if indi-
cated. A tight iliopsoasmuscle may lead toworsening lumbar
lordosis, increasing pain, and adding force being applied to
vertebrae already prone to fracture.
For patients with compression fractures and/or axial back
pain, treatment should be divided into acute and chronic.
Acute compression fractures warrant ﬂexion/extension x-
rays, as outlined above. In the setting of signiﬁcant spinal
instability, a cruciform anterior stabilization hyperextension
(CASH) brace or Jewett brace should be considered. Both the
CASH and the Jewett brace limit ﬂexion, and thus do not load
the oft-fractured anterior column of the spine, permitting
healing. Proper ﬁtting of these braces by a certiﬁed orthotist
prevents unwanted vertebral movement and optimizes
healing. Most compression fractures, however, are not un-
stable, so bracing is usually used more for comfort and to
prevent progression of the kyphotic deformity. A soft corset
brace can provide proprioceptive feedback to prevent spinal
ﬂexion and reduce pain. In deconditioned cGVHD patients,
braces may not be helpful, as they can be restrictive and
contribute to disuse muscle atrophy. Persons at risk for
compression fractures and those who have had compression
fractures should be involved in extension-based truncal ex-
ercises and not perform any ﬂexion exercises. Flexion exer-
cises, even combined with extension, are contraindicated as
they increase deformity and risk of fracture [59]. Lifestyle
modiﬁcations should be implemented to eliminate the need
to lift or carry heavy objects.
For patients in acute pain, opioid analgesics should be
provided as the clinical picture warrants, and patients should
lay supine for 15-mintue intervals multiple times a day.
Activity should be gradually introduced as the patient’s pain
level tolerates and with proper restrictions and/or bracing if
instability is present. In healthy patients, kyphoplasty and
vertebroplasty may decrease pain earlier than conservative
treatment, but they are of not clearly superior to conservative
treatment in the long term [60,61]. These procedures are
only indicated in patients with an acute, unhealed
compression fracture causing pain at the level of fracture that
is not controlled by other measures [62]. A surgical referral
may be warranted in patients who appear unstable or have
neurological symptoms or an abnormal neurological exam.
Ensuring that chronic pain from osteopenia/osteoporosis is
properly treated is important, as chronic pain itself is asso-
ciated with bone density loss [63].
AVN of joints can be treated operatively or non-
operatively. Joint replacement is deﬁnitive treatment for
AVN, though considerations must be made for whether or
not the patient is healthy enough to tolerate both surgery and
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tions include joint-sparing surgery, and the surgical inter-
ventionwill ultimately depend on the degree of AVN and the
patient’s functional status [51].
The most important nonoperative treatment for AVN of
weight-bearing joints is multidisciplinary rehabilitation,
including assistive and mobility devices, physical therapy to
strengthen the surrounding musculature of the affected
joint(s), environmental modiﬁcations, and general strength-
ening and cardiovascular conditioning. Relative rest and icing
painful joints are also appropriate. A corticosteroid injection,
though seemingly counter-intuitive given the risk of cortico-
steroids inducing AVN, can also be beneﬁcial in reducing
inﬂammation around the joint, and, thus, pain. Ultrasound
guidance is recommended to ensure that the corticosteroid is
injected into the bursa surrounding the joint, which is often
inﬂamed. Oral corticosteroids may not satisfactorily penetrate
the bursa, thereby necessitating an injection to reduce local
inﬂammation. Injections should be considered if the femoral
or humeral heads are not ﬂattened, as at the point ofﬂattening
the joint anatomy is so fundamentally altered that the main
generator of pain is not the inﬂamed bursa, but rather the
abnormal head of the bone grinding in the acetabulum or
glenoid fossa.CARDIAC AND PULMONARY
Clinical Manifestations
Most cardiopulmonary issues related to cGVHD and HSCT
are related to decreased aerobic capacity and performance
status from a lack of physical activity [2,64]. As mentioned
earlier, inactivity can cause profound muscle atrophy, as well
as a decline in cardiac performance, with increased resting
heart rate, decreased stroke volume, and decreasedmaximum
oxygen consumption (VO2max) [65]. Fatigue can also occur, in
part due to anemia and associated decreased tissue oxygen-
ation [66]. Furthermore, patients may have lower extremity
edema from hepatic GVHD causing congestion, demanding
more energy for ambulation [34] and potentially increasing
cardiac afterload.
Persons with cGVHD may have impaired function of res-
piratory muscles, with the muscles of expiration more
affected than those of inspiration [67]. This is sometimes
associated with known cGVHD complications, such as poly-
myositis and myasthenia gravis, but also occurs independent
of other comorbidities. As pulmonary decline hinders pa-
tients’ ability to participate in physical and occupational
therapy, addressing these impairments is essential to prevent
the patient from further physical decompensation. Pulmonary
complications of GVHD and HSCT can of course be a direct
result of the disease, affecting up to 60% of patients, and
potentially leading to bronchiolitis obliterans (BO) [68]. Pul-
monary function tests are abnormal and indicate an obstruc-
tive process in patients with pulmonary cGVHD [2,10].Treatment
As outlined above in the “Muscle” section, mobilization of
the hospitalized patient can prevent muscle mass loss and
boost performance. For inpatients with cGVHD and pulmo-
nary compromise, good pulmonary hygiene, including suc-
tioning and mucous clearance, and pulmonary physical
therapy consisting of vibration and pulmonary hygiene
(suction, incentive spirometry, manual percussion), have
been shown to be effective in preventing infection and
improving symptom burden in patients with BO [69].For outpatients, aerobic activity should still be empha-
sized to reduce the risk of mortality from cardiovascular
disease and improve function. This can be done through a
structured physical therapy or patient-directed program. The
compliance rate of patients after HSCT and on glucocorticoid
therapy undergoing a structured physical therapy program
was found to be 54%, with hospital readmission being the
most common reason for noncompliance [70].
Despite the potential beneﬁts of a structured exercise
program, little data exist speciﬁc to patients with cGVHD.
There are, however, data to suggest that even self-directed
exercise immediately after BMT reduces symptom burden
[71,72]. One study looked at an exercise program interven-
tion for patients undergoing HSCT both while in the hospital
and after discharge, and it noted improved muscle strength,
aerobic capacity, and functional performance (stair climb-
ing), with reduced severity of diarrhea and days on parental
nutrition. The outcomes, however, were statistically signiﬁ-
cant on the day of discharge from the hospital, and the im-
plications of exercise on patients with cGVHD are not
clariﬁed by this study [71]. Another study evaluated mice
models and showed that an 11-week exercise program
resulted in less physical deterioration than in the control,
nonexercise group [73].
Cardiac rehabilitation referral should be considered in
patients with congestive heart failure or who are at risk of
developing dangerous arrhythmias. The beneﬁts of cardiac
rehabilitation in the general population has been shown to
reduce mortality, boost exercise capacity, reduce symptoms,
reduce stress, boost self-worth, and improve safety [65]. Ef-
fects are typically observed within 6 to 10 weeks but may be
seen as early as 10 days of initiating a program [74]. This has
not been studied speciﬁcally in patients with cGVHD.
Outpatient pulmonary rehabilitation should be consid-
ered in patients with BO and/or who have maximum O2
consumption of 75% or less during exercise, a forced expi-
ratory volume at 1 second of less than 2000 mL, or an forced
expiratory volume at 1 second to forced vital capacity ratio of
less than 60% [52]. One trial studied 11 GVHD patients with
BO who underwent a standard outpatient pulmonary reha-
bilitation program and found statistically signiﬁcant
improvement in 6-minute walk test distance and patient-
reported physical functioning, including dyspnea [69].
CONCLUSION
Despite the numerous potential complications of cGVHD,
relatively little is known about patient medical rehabilita-
tion. There is a dearth of cGVHD rehabilitation knowledge
including diagnosis, treatment, and monitoring of progress.
More research is needed in these areas to ensure optimal
patient care and potentially develop protocols. Enhancing
patient function and quality-of-life through an adequate
rehabilitation program has the potential to spare other sys-
temic therapies like corticosteroids, which may cause
considerable toxicity. Thus, given the known health beneﬁts
of patient mobilization and exercise, it is entirely possible
that a comprehensive, customized medical rehabilitation
plan after allogeneic transplantation may prevent the con-
sequences of advanced cGVHD and improve patient
outcomes.
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